PaxMedica, Inc. Common Stock
PaxMedica, Inc. Common Stock
Your view on PXMD
Overview
What the company does, where it operates, and who runs it.
About PaxMedica, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Howard J. Weisman
- Headquarters
- 303 South Broadway, Tarrytown, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Howard J. Weisman
- Headquarters
- 303 South Broadway, Tarrytown, NY, US
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms.
The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis.
It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications.
The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for PaxMedica, Inc. Common Stock, and the rating behind it. PXMD last traded at $0.0003; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for PaxMedica, Inc. Common Stock. Starting points for PaxMedica, Inc. Common Stock: EPS -$11.00, beta -0.56 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for PaxMedica, Inc. Common Stock. PaxMedica, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for PaxMedica, Inc. Common Stock. Trailing twelve-month EPS for PaxMedica, Inc. Common Stock stands at -$11.00. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for PaxMedica, Inc. Common Stock. PaxMedica, Inc. Common Stock has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
PaxMedica, Inc. Common Stock valued side by side against its closest peers. PaxMedica, Inc. Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold PaxMedica, Inc. Common Stock, and how their positions are changing. At a $37,879 market value, institutional positions materially move PaxMedica, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by PaxMedica, Inc. Common Stock executives and directors. Shares of PaxMedica, Inc. Common Stock have traded between $0.0001 and $0.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming PaxMedica, Inc. Common Stock. PaxMedica, Inc. Common Stock is a $37,879 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming PaxMedica, Inc. Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for PaxMedica, Inc. Common Stock. Coverage tracks PaxMedica, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.